| Can-Fite BioPharma (NYSE American: CANF) Granted Patents for Sexual Dysfunction Drug |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, has been granted patents in Canada, South Korea, and Israel for its patent titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction" for its drug candidate CF602. Patents were also issued in the U.S., Australia, China, Hong Kong, and Japan over the past few years.
Why It Matters: Grand View Research Inc. estimates the value of the erectile dysfunction therapeutic market will reach approximately $3.2 billion by 2022. According to the American Diabetes Association, approximately 30 million Americans have diabetes mellitus in the U.S. It is estimated that 35-75% of men with diabetes mellitus suffer from erectile dysfunction.
Key Quote:: “CF602 has a unique mechanism of action that makes it suitable to potentially treat sexual dysfunction safely in patients with diabetes mellitus. This is a clear and unmet need in the market today, as the leading sexual dysfunction drugs can be contraindicated for diabetics. We are now actively looking for and evaluating potential strategic partners that may in-license and develop CF602 in this indication.” – Dr. Pnina Fishman, CEO
The Backstory: CANF’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. CANF’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Catasys (NASDAQ: CATS) Appoints Industry Executive Gus Giraldo to Board |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced the appointment of Gustavo Giraldo to its Board of Directors, replacing Sharon Gabrielson. The number of Board members remains at seven.
Why It Matters: Giraldo currently serves as President of Behavorial and Specialty Health at Magellan Health, Inc., a Fortune 500 healthcare company focused on special populations, complete pharmacy benefits and other specialty areas of healthcare. In this role, he is responsible for the strategic development and profitable growth of Magellan Healthcare’s health plan, employer, provider segments, state carve-out behavioral health and federal markets. Mr. Giraldo previously served as Chief Operating Officer for Chubb’s Latin American life, accident and health business and, prior to that, was at Cigna for 18 years, serving in various roles domestically and abroad.
Key Quote: “As President of the largest independent managed care behavioral health organization, Gus brings an area of industry expertise that we currently lack on the Board, as well as over 20 years of leadership in the healthcare industry. We believe his strong track record of initiating, leading and growing domestic and global healthcare businesses; deep understanding of the dynamics of varied healthcare systems around the world, consumer marketing, product innovation and analytics; and extensive industry relationships will prove to be valuable additions to our Board as we continue to execute on our growth initiatives.” – Terren Peizer, Chairman & CEO
The Backstory: CATS is a leading AI and technology-enabled healthcare company whose mission is to help improve the health and save the lives of as many people as possible. Its Catasys PRETM (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages people who aren’t getting the care they need. By combining predictive analytics with human engagement, Catasys delivers improved member health and validated outcomes and savings to healthcare payers.
Disclosure
Catasys (CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in February 2017, for RedChip investor awareness services and consulting services.
|
|
| |
|
| Immuron (NASDAQ: IMRN) Plans Phase 3 Trial for IMM-124E to Prevent Travelers’ Diarrhea |
| |
|
Immuron (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that the company recently completed a Pre-IND meeting with the U.S. Food and Drug administration (FDA) regarding its investigational drug IMM-124E which the company is developing to treat travelers’ diarrhea (TD).
Why It Matters: TD affects between 30% and 70% of over one billion international travelers every year. TD is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp., the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with TD as they may be contracted while travelling and initial symptoms are often indistinguishable.
Key Quote: “Our recent interactions with FDA were exceedingly helpful in refining plans for this Phase 3 trial. To our knowledge, IMM-124E, once successfully shown to work in subjects traveling to endemic areas, and successfully approved, would be the first and only FDA-approved pharmaceutical product to specifically prevent diarrhea.” Dr. Gary Jacob, CEO
The Backstory: Travelan® and IMM-124E, Immuron’s drug candidate presently in clinical development for TD, are one and the same active pharmaceutical ingredient. The Company currently markets and sells Travelan® as a Therapeutic Goods Administration (TGA) listed medicine for prevention of TD in Australia, and also markets Travelan® in the U.S. and Canada as a dietary supplement, and natural health product, respectively, for digestive tract protection.
Disclosure
Immuron Ltd. (IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee, beginning in June 2017, for investor awareness services.
|
|
| |
|
| SinglePoint (OCTQB: SING) Subsidiary Direct Solar Making Major Headway as Expansion Continues |
| |
|
SinglePoint (OTCQB: SING) subsidiary Direct Solar, a leading residential and commercial solar brokerage, continues to exceed revenue growth targets and has been pivotal to improving the Company’s financials.
Recent Highlights:
- Contracts Originated $4,965,975 (installs set for Q4 and Q1 2020)
- Opened in three new states
- Launched high school partnership program with 47 Texas based high schools
- Signed MOU with SchollyMe to develop online and mobile solar purchasing ability
- Launched Direct Solar Capital and Direct Solar Commercial
Key Quote: “We have been on an upswing as more people are finding out about Direct Solar and what we bring to the market. From homeowners to developers and commercial building owners, we have a solution. We believe the market for residential alone is around 100 Million homes. With the complexity around buying solar, we believe Direct Solar is the key to helping solar customers easily acquire the best solution for their needs.” – Pablo Diaz, CEO of Direct Solar
The Backstory: SING is a technology and acquisition company with a focus on acquiring companies that will benefit from management, capital and technology integration. The company’s portfolio includes mobile payments, industrial hemp and renewable energy solutions. Through acquisitions into horizontal markets, SING is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base.
Disclosure
SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.
|
|
| |
|
| ChineseInvestors.com (OTCQB: CIIX) Subsidiary CBD Biotech Featured in Wall Street Journal |
| |
|
CBD Biotech, a subsidiary of ChineseInvestors.com (OTCQB:CIIX), an established financial news and investment portal, as well as a leading industrial hemp retailer for the Chinese-speaking community, was featured in a Wall Street Journal report on November 13, 2019, entitled "China Says No to Marijuana but Lets Its Cannabis Industry Bloom - Farmers, Companies Increase Hemp-related Investments."
The article and accompanying video can be found at www.wsj.com/articles/china-lets-its-cannabis-industry-bloom-but-says-no-to-marijuana-11573567906
Key Quote: “As one of the first movers in the legal industrial hemp skincare and cosmetics market, we are honored to be featured in this recent Wall Street Journal report and believe that this mention validates our efforts in China over the past few years.” – Summer Yun, CEO of CBD Biotech
The Backstory: Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.
Disclosure
ChineseInvestors.com, Inc. (CIIX) is a client of RedChip Companies. CIIX pays RedChip a cash fee of $10,000 monthly, beginning in May 2019, for six (6) months of investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Work hard, be a long-term thinker, develop tenacity and remember nothing happens without taking calculated risks."
-Phil Sassower, Chairman Phoenix Group |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
